HIPEC FOR
PERITONEAL MESOTHELIOMA
Peritoneal mesothelioma was once considered uniformly fatal within 12 months. CRS-HIPEC has fundamentally changed this — with specialist centres reporting median overall survival of 40–92 months for epithelioid subtype and 5-year survival exceeding 50% in optimal candidates.
analyticsAt a Glance
- check_circlePeritoneal mesothelioma accounts for 20–30% of all mesothelioma cases — more common in women and younger patients than pleural mesothelioma
- check_circleEpithelioid subtype: median OS 40–92 months with CRS-HIPEC; biphasic/sarcomatoid: 10–15 months regardless of treatment
- check_circleCRS-HIPEC is the only treatment with proven survival benefit — systemic chemotherapy alone has median OS of 12–18 months
- check_circleAsbestos exposure accounts for only 50–60% of cases — many have no identified carcinogen exposure
What Is Peritoneal Mesothelioma and Who Gets It?
Peritoneal mesothelioma is a malignancy arising from the mesothelial cells lining the peritoneal cavity — not from mucosal or glandular cells as in adenocarcinoma. It is distinct from pleural mesothelioma in biology, demographics, and treatment response. Peritoneal mesothelioma accounts for 20–30% of all mesothelioma diagnoses and has a strikingly different demographic profile from its pleural counterpart.
“Peritoneal mesothelioma is one of the few cancers where the treatment has changed prognosis from 'months' to 'years' — and where the centre's experience may be the single most important determinant of whether that transformation applies to a specific patient.”
Demographics: Different from Pleural Mesothelioma
Unlike pleural mesothelioma — which predominantly affects older men with occupational asbestos exposure — peritoneal mesothelioma affects women in 40–50% of cases, has a younger median age at diagnosis (55–65 years), and lacks asbestos exposure in up to 40–50% of patients. Non-asbestos-related peritoneal mesothelioma may be linked to simian virus 40 (SV40), genetic predisposition (germline BAP1 mutations), or have no identified aetiology.
Why Peritoneal Mesothelioma Responds to CRS-HIPEC
Peritoneal mesothelioma behaves as a locoregional disease for most of its natural history — it spreads across peritoneal surfaces but rarely metastasises haematogenously to liver parenchyma, lung, or bone until very late. This local pattern makes it theoretically resectable with peritonectomy — and the direct intraperitoneal delivery of HIPEC chemotherapy (cisplatin + doxorubicin) addresses residual microscopic disease that surgery alone cannot clear.
Histological Subtypes and Their Impact on CRS-HIPEC Outcomes
Histological subtype is the single most important prognostic determinant in peritoneal mesothelioma — guiding the decision to pursue CRS-HIPEC versus systemic chemotherapy.
| Subtype | Frequency | Key Features | Median OS with CRS-HIPEC | CRS-HIPEC Role |
|---|---|---|---|---|
| Epithelioid | 60–70% | Tubular, papillary, or solid patterns; well-defined cell borders; best prognosis | 40–92 months (centre-dependent) | First-line curative intent — strongest evidence base |
| Biphasic | 20–25% | Mixed epithelioid and sarcomatoid components; intermediate prognosis | 15–25 months | Selected cases — discuss at specialist MDT; benefit lower than epithelioid |
| Sarcomatoid | 5–10% | Spindle cell pattern; highly aggressive; rare peritoneal predominance | 10–15 months | CRS-HIPEC generally not recommended — systemic chemotherapy preferred |
| Well-differentiated papillary mesothelioma (WDPM) | <5% | Borderline malignancy; papillary architecture; indolent behaviour | Often >10 years | Conservative surgery — HIPEC not always required; excellent prognosis without aggressive treatment |
CRS-HIPEC Outcomes for Peritoneal Mesothelioma: Published Data
The following data are from the largest published series and international registries for CRS-HIPEC in peritoneal mesothelioma.
Overall Survival by Histological Subtype and CC Score — PSOGI Registry
Source: Helm JH et al., Ann Surg Oncol 2015; Yan et al. 2009 pooled analysis; approximate values
- Epithelioid, CC-0: median OS63–92 mo
- Epithelioid, CC-1: median OS40–52 mo
- Biphasic, CC-0: median OS26 mo
- Systemic chemo alone (historic control)12–18 mo
Patient Selection for CRS-HIPEC in Peritoneal Mesothelioma
Selection criteria at high-volume mesothelioma CRS-HIPEC centres — where experience with this rare diagnosis is concentrated.
| Criterion | Favourable | Caution / Less Suitable |
|---|---|---|
| Histological subtype | Epithelioid | Biphasic: discuss; sarcomatoid: generally not offered CRS-HIPEC |
| PCI | No absolute upper limit for epithelioid — PCI up to 30–35 can achieve CC-0 at high-volume centres | Very high PCI (>35) with anticipated CC-2+ — palliative approach preferred |
| Prior chemotherapy | Not required — surgery is first line at specialist centres for fit patients | Multiple prior lines with poor response — may indicate aggressive biology |
| Performance status | ECOG 0–1 | ECOG 2+: increased surgical risk; careful MDT review required |
| BAP1 status | BAP1 loss (IHC) — associated with epithelioid histology and better prognosis after CRS-HIPEC | BAP1 retained in sarcomatoid — germline testing for familial cases |
| Extra-abdominal spread | Absent — no lymph node, pleural, or parenchymal metastases | Mediastinal nodes, pleural deposits, or parenchymal metastases: contraindication to curative CRS |
CRS-HIPEC vs Systemic Chemotherapy for Peritoneal Mesothelioma
The treatment decision for peritoneal mesothelioma depends almost entirely on histological subtype and patient fitness — as the survival advantage of CRS-HIPEC over chemotherapy is dramatic for epithelioid disease.
CRS-HIPEC (Epithelioid)
- Median OS 40–92 months — potentially curativeCRS-HIPEC transforms peritoneal mesothelioma from a 12-month disease to one where 5-year survival exceeds 50% in optimal CC-0 epithelioid cases at high-volume centres.
- Locoregional control prevents symptomatic ascitesComplete peritonectomy eliminates the disease source of malignant ascites — a major quality-of-life benefit compared to repeated paracentesis under systemic therapy.
- Subsequent chemotherapy remains availablePatients who recur after CRS-HIPEC can still receive systemic chemotherapy — the surgery does not preclude later systemic treatment, whereas chemotherapy prior to surgery may worsen resectability.
- Option for repeat CRS in slow recurrenceEpithelioid recurrence after complete CRS is often slow and can be managed with repeat CRS at 2–5 years in selected cases at the same specialist centre.
Systemic Chemotherapy (All Subtypes)
- First-line pemetrexed + cisplatin achieves 40–45% ORRStandard systemic therapy for mesothelioma; median OS 12–18 months — appropriate for sarcomatoid subtype, poor performance status, or patients declining surgery.
- No surgical risk for frail patientsMajor CRS-HIPEC carries 2–5% operative mortality risk — systemic chemotherapy is the appropriate approach for patients who cannot tolerate this.
- Checkpoint inhibitor combinations emergingNivolumab + ipilimumab (CheckMate 743 subgroup) has shown activity in mesothelioma — being evaluated in the peritoneal setting as induction or adjuvant therapy alongside CRS-HIPEC.
- Palliative benefit independent of histologySystemic chemotherapy provides palliation — reducing ascites, controlling symptoms — across all histological subtypes, including those for whom surgery is not appropriate.
More from the Peritoneal Oncology Resource Library
Continue exploring peritoneal oncology — from PCI scoring and surgery to patient selection and access.
Frequently Asked Questions
Common questions from peritoneal mesothelioma patients navigating diagnosis and treatment options.
About Peritoneal Mesothelioma and CRS-HIPEC
I have peritoneal mesothelioma but no history of asbestos exposure — is this common?
Yes — up to 40–50% of peritoneal mesothelioma patients have no identified asbestos exposure. Unlike pleural mesothelioma, where >80% of cases have occupational asbestos exposure, peritoneal mesothelioma has a more varied aetiology. Other associations include germline BAP1 mutations (a hereditary cancer predisposition syndrome), simian virus 40 (SV40) exposure (through early polio vaccines), and possibly radiation exposure. In many cases — particularly in women with epithelioid peritoneal mesothelioma and no asbestos history — no specific carcinogen is identified. This does not change treatment eligibility or prognosis.
How do I know if a centre has enough experience with peritoneal mesothelioma to perform my surgery?
Peritoneal mesothelioma is rare — even at high-volume CRS-HIPEC centres, individual surgeons may see only 5–15 mesothelioma cases per year. The minimum threshold for mesothelioma-specific CRS-HIPEC experience is not formally defined, but generally a centre should perform at least 20–30 CRS-HIPEC cases annually overall with documented mesothelioma-specific series. Ask the centre specifically: 'How many peritoneal mesothelioma CRS-HIPEC procedures do you perform per year?' and 'Can you share your published or audited outcomes data for mesothelioma?' CancerFax evaluates mesothelioma-specific experience before recommending any centre for this indication.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Peritoneal Mesothelioma Diagnosis? Specialist Review Is Essential.
Peritoneal mesothelioma is rare — most oncologists see fewer than five cases in a career. CancerFax connects patients with specialist peritoneal oncology surgeons at high-volume CRS-HIPEC centres with specific mesothelioma experience in China and India.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.